Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.

Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, Wick W, Weller M, Steinbach JP.

Brain. 2009 Jun;132(Pt 6):1509-22. doi: 10.1093/brain/awp093. Epub 2009 May 4.

PMID:
19416948
[PubMed - indexed for MEDLINE]
Free Article
2.

mTOR as a positive regulator of tumor cell responses to hypoxia.

Abraham RT.

Curr Top Microbiol Immunol. 2004;279:299-319. Review.

PMID:
14560965
[PubMed - indexed for MEDLINE]
3.

Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.

Bertoni E, Salvadori M.

J Nephrol. 2009 Jul-Aug;22(4):457-62. Review.

PMID:
19662600
[PubMed - indexed for MEDLINE]
4.

Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives.

Ronellenfitsch MW, Steinbach JP, Wick W.

Target Oncol. 2010 Sep;5(3):183-91. doi: 10.1007/s11523-010-0154-5. Epub 2010 Sep 19. Review.

PMID:
20853178
[PubMed - indexed for MEDLINE]
5.

Current status of mammalian target of rapamycin inhibitors in lung cancer.

Gómez-Martín C, Rubio-Viqueira B, Hidalgo M.

Clin Lung Cancer. 2005 Sep;7 Suppl 1:S13-8. Review.

PMID:
16159415
[PubMed - indexed for MEDLINE]
6.

Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.

Witzig TE, Kaufmann SH.

Curr Treat Options Oncol. 2006 Jul;7(4):285-94. Review.

PMID:
16916489
[PubMed - indexed for MEDLINE]
7.

Current status and challenges associated with targeting mTOR for cancer therapy.

Dowling RJ, Pollak M, Sonenberg N.

BioDrugs. 2009;23(2):77-91. doi: 10.2165/00063030-200923020-00002. Review.

PMID:
19489650
[PubMed - indexed for MEDLINE]
8.

An expanding role for mTOR in cancer.

Guertin DA, Sabatini DM.

Trends Mol Med. 2005 Aug;11(8):353-61. Review.

PMID:
16002336
[PubMed - indexed for MEDLINE]
9.

Targeting mTOR signaling for cancer therapy.

Huang S, Houghton PJ.

Curr Opin Pharmacol. 2003 Aug;3(4):371-7. Review.

PMID:
12901945
[PubMed - indexed for MEDLINE]
10.

Receptor tyrosine kinases as therapeutic targets in malignant glioma.

Ren H, Yang BF, Rainov NG.

Rev Recent Clin Trials. 2007 May;2(2):87-101. Review.

PMID:
18473993
[PubMed - indexed for MEDLINE]
11.

[Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].

Shuuin T, Karashima H.

Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9. Review. Japanese.

PMID:
19620795
[PubMed - indexed for MEDLINE]
12.

mTOR as a target for cancer therapy.

Houghton PJ, Huang S.

Curr Top Microbiol Immunol. 2004;279:339-59. Review.

PMID:
14560967
[PubMed - indexed for MEDLINE]
13.

mTOR and cancer therapy.

Easton JB, Houghton PJ.

Oncogene. 2006 Oct 16;25(48):6436-46. Review.

PMID:
17041628
[PubMed - indexed for MEDLINE]
14.

The potential role of mTOR inhibitors in non-small cell lung cancer.

Gridelli C, Maione P, Rossi A.

Oncologist. 2008 Feb;13(2):139-47. doi: 10.1634/theoncologist.2007-0171. Review.

PMID:
18305058
[PubMed - indexed for MEDLINE]
Free Article
15.

Mammalian target of rapamycin (mTOR) Inhibitors.

Dutcher JP.

Curr Oncol Rep. 2004 Mar;6(2):111-5. Review.

PMID:
14751088
[PubMed - indexed for MEDLINE]
16.

Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected.

Stoeltzing O, Meric-Bernstam F, Ellis LM.

Cancer Cell. 2006 Aug;10(2):89-91. Review.

PMID:
16904605
[PubMed - indexed for MEDLINE]
Free Article
17.

[Rapamycine and mTOR inhibitors: from bench to bedside].

Pallet N, Beaune P, Legendre C, Anglicheau D.

Ann Biol Clin (Paris). 2006 Mar-Apr;64(2):107-15. Review. French.

PMID:
16556521
[PubMed - indexed for MEDLINE]
18.

The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications.

Nakamura JL.

Expert Opin Ther Targets. 2007 Apr;11(4):463-72. Review.

PMID:
17373877
[PubMed - indexed for MEDLINE]
19.

Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme.

Panner A, Parsa AT, Pieper RO.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1313-22. Review.

PMID:
17020463
[PubMed - indexed for MEDLINE]
20.

[mTOR signal pathway and its inhibitors in antitumor therapy: a review].

Huang JJ, Lin TY.

Ai Zheng. 2007 Dec;26(12):1397-403. Review. Chinese.

PMID:
18076811
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk